| HOME >> BIOLOGY >> TECHNOLOGY |
Gain on sale of equity investment -- 17,662 -- 17,662
Net income/(loss) $(11,274) $8,340 $(49,315) (16,482)
Basic and diluted net income/(loss)
per share $(0.31) $0.23 $(1.34) $(0.46)
Shares used in computing basic and
diluted net income/(loss) per
share 36,898 36,109 36,787 36,046
Condensed Consolidated Balance Sheets
(in thousands)
December 31, December 31,
2007 2006
(unaudited) (Note 1)
Cash, cash equivalents and marketable
securities $145,813 $182,876
Receivables, prepaid and other assets 11,644 7,317
Property and equipment, net 3,060 3,262
Goodwill and other intangibles, net 12,192 12,192
Total assets $172,709 $205,647
Other liabilities $14,802 $10,255
Total deferred revenue -- 5,593
Restructuring liabilities 4,413 --
Stockholders' equity 153,494 189,799
Total liabilities and stockholders' equity $172,709 $205,647
Footnotes
(A) Reconciliation of GAAP and non-GAAP net income/(loss) and net
income/(loss) per share (in thousands, except per share amounts)
Three Months Ended Twelve Months Ended
December 31, December 31,
'/>"/>
| SOURCE Maxygen, Inc. Copyright©2008 PR Newswire. All rights reserved |